Wednesday, June 20, 2018 -- Light-activated AU-011 for the treatment of primary choroidal melanoma was well tolerated with no severe adverse events, while showing promising early efficacy results, in a phase 1b/2 trial, Aura Biosciences announced in a press release.The open-label, multicenter trial is evaluating the safety and efficacy of single and multiple ascending doses of AU-011 in 30 adult patients with small to medium primary choroidal melanoma.Interim data showed two subjects in the first multiple-ascending-dose cohort had evidence of tumor reduction after 3 months, the release said. In addition, subtherapeutic
Wednesday, June 20, 2018 -- Pembrolizumab (Keytruda) induced a median overall survival (OS) of 32.7 months versus 15.9 months for ipilimumab (Yervoy) in patients with unresectable stage III-IV melanoma, according to 4-year survival results from the KEYNOTE-006 trial presented at the 2018 ASCO Annual Meeting.
Thursday, June 21, 2018 -- Ashani Weeraratna, Ph.D. The Ira Brind professor and Co-program leader of the Immunology, Microenvironment and Metastasis Program The Wistar Institute Member of Wistar’s Melanoma Research Center Philadelphia MedicalResearch.com: What is the background for this study? What are the main findings? Response: This study shows for the first time that older patients, especially those who have had prior MAPKi therapy fare better than younger patients when treated with anti-PD1. We found that tumors in younger patients and younger mice have higher levels of Tregulatory cells, the cells that regulate other immune cells. This is not true systemically, only within the tumor microenvironment. We were surprised because we expected that, as with targeted therapy, older patients would have a poorer response to immunotherapy, given what we
Thursday, June 21, 2018 -- Aura Biosciences announced promising safety and efficacy outcomes in a phase 1b/2 trial for AU-011, their first-in-class therapy for primary choroidal melanoma.